Your browser doesn't support javascript.
loading
The predictive value of vessels encapsulating tumor clusters in treatment optimization for recurrent early-stage hepatocellular carcinoma.
Chen, Zhi-Yuan; Guo, Zhi-Xing; Lu, Liang-He; Mei, Jie; Lin, Wen-Ping; Li, Shao-Hua; Wei, Wei; Guo, Rong-Ping.
Afiliação
  • Chen ZY; Department of Gastroenterology, Hunan Provincial People' Hospital, Changsha, China.
  • Guo ZX; The First Affiliated Hospital of Human Normal University, Changsha, China.
  • Lu LH; State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Mei J; State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Lin WP; Department of Ultrasound, Sun Yat-sen University Cancer Center, Guangzhou, China.
  • Li SH; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
  • Wei W; State Key Laboratory of Oncology in South China, Guangzhou, China.
  • Guo RP; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Cancer Med ; 10(16): 5466-5474, 2021 08.
Article em En | MEDLINE | ID: mdl-34212527
ABSTRACT

BACKGROUND:

The predictive value of vessels encapsulating tumor clusters (VETC) in recurrent early-stage hepatocellular carcinoma (HCC) remains unclear. Therefore, the aim of the present study was to investigate the prognostic significance of VETC in patients with recurrent early-stage HCC after repeat hepatic resection (RHR) or radiofrequency ablation (RFA).

METHODS:

From December 2005 to December 2016, 138 patients receiving RHR and 188 patients receiving RFA were recruited. VETC was evaluated by immunohistochemical staining for CD34. The survival outcomes of patients with VETC pattern or not were investigated.

RESULTS:

There was no significant difference between the RHR and RFA groups in disease-free survival (DFS) or overall survival (OS) as determined by the univariate analysis of the whole cohort. In the subgroup analysis of the VETC-positive cohort, the patients in the RHR group showed a longer median DFS time in contrast to those in the RFA group (15.0 vs. 5.0 months, p = 0.001). Similarly, the patients in the RHR group showed a longer median OS time in contrast to those in the RFA group (39.5 vs. 19 months, p = 0.001). In the VETC-negative cohort, no significant differences in DFS and OS rates between the RHR and RFA groups were observed (p > 0.05).

CONCLUSIONS:

The results of our study suggested that RHR was relatively safe and superior to RFA in improving survival outcomes for recurrent early-stage HCC after initial hepatectomy. Furthermore, the VETC pattern may represent a reliable marker for selecting HCC patients who may benefit from RHR.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Fígado / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Fígado / Neoplasias Hepáticas / Recidiva Local de Neoplasia Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Med Ano de publicação: 2021 Tipo de documento: Article País de afiliação: China